Aspire Biopharma Holdings (ASBP) Change in Account Payables (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Change in Account Payables of -$139535.0 for Q1 2026, down 112.44% year-over-year from $1.1 million in Q1 2025, and down 199.91% quarter-over-quarter from -$46526.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Change in Account Payables (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Change in Account Payables for 5 consecutive years, with -$139535.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 112.44% year-over-year to -$139535.0; the TTM figure through Mar 2026 stood at -$1.6 million (down 176.58% YoY), while the FY2025 annual figure was -$323776.0, down 135.73% from the prior year.
- Change in Account Payables eased to -$139535.0 in Q1 2026 per ASBP's latest filing, from -$46526.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.1 million in Q1 2025 and bottomed at -$1.3 million in Q3 2025.
- Historically, Change in Account Payables has averaged $40107.3 across 5 years, with a median of $30000.0 in 2022.
- Annual changes were most pronounced in 2024 — Change in Account Payables surged 3508.21% — and 2025, when it tumbled 2219.6%.
- Aspire Biopharma Holdings' Change in Account Payables stood at $30000.0 in 2022, then declined by 9.99% to $27002.0 in 2023, then soared by 3508.21% to $974289.0 in 2024, then sank by 104.78% to -$46526.0 in 2025, then plunged by 199.91% to -$139535.0 in 2026.
- Business Quant data shows ASBP's Change in Account Payables at -$139535.0 in Q1 2026, -$46526.0 in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 127,589.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 127,589.00 |
| Jun 30, 2026 | 127,589.00 |
| Mar 31, 2026 | -139,535.00 |
| Mar 31, 2026 | -139,535.00 |
| Dec 31, 2025 | -46,526.00 |
| Dec 31, 2025 | -46,526.00 |
| Sep 30, 2025 | -1.32 Mn |
| Sep 30, 2025 | -1.32 Mn |
| Jun 30, 2025 | -80,386.00 |
| Jun 30, 2025 | -80,386.00 |
| Mar 31, 2025 | 1.12 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 974,289.00 |
| Dec 31, 2024 | 974,289.00 |
| Sep 30, 2024 | -56,849.00 |
| Sep 30, 2024 | -56,849.00 |
| Jun 30, 2024 | 30,529.00 |
| Jun 30, 2024 | 30,529.00 |
| Mar 31, 2024 | -41,773.00 |
| Mar 31, 2024 | -41,773.00 |